66 suggested that low circulating irisin levels lead to non-alcoholic fatty liver and that Nicotinamide adenine dinucleotide + boosting therapy improves non-alcoholic fatty liver disease via stimulating a novel Fndc5/irisin. This evidence concerns the gene FNDC5 and metabolic dysfunction-associated steatotic liver disease.